Neuraxis

Neuraxis Days Payable Outstanding

The Days Payable Outstanding (DPO) of Neuraxis (NRXS) as of Nov 17, 2026 is 90.37. In the previous year, Days Payable Outstanding (DPO) was 601.89 — a change of -84.99% (lower).

Days Payable Outstanding

90.37

YoY

-84.99%

Last updated:

Days Payable Outstanding (DPO) of Neuraxis is 2025 90.37 . Days Payable Outstanding (DPO) of Neuraxis was 2024 601.89 . It decreases by -84.99% lower compared to the previous year.

The Neuraxis Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2020
124.85 USD
Jan 1, 2021
377.59 USD
Jan 1, 2022
1,956.25 USD
Jan 1, 2023
1,448.98 USD
Jan 1, 2024
601.89 USD
Jan 1, 2025
90.37 USD
The Neuraxis Days Payable Outstanding history
YEARDays Payable OutstandingYoY
90.37-84.99%
601.89-58.46%
1,448.98-25.93%
1,956.25+418.08%
377.59+202.44%
124.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Days Payable Outstanding (DPO) of Neuraxis is 90.37 in 2025.

Days Payable Outstanding (DPO) of Neuraxis changed from 601.89 to 90.37, representing a -84.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis